wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 101 - 150 of 319.

Physics/Materials Science - Business/Economics
14.06.2017
From the garage to the world
In 1999, PSI researchers founded the spin-off firm SwissNeutronics. Today the company has a staff of 15, sells high-precision components to research institutions all over the world, and still is based in the small town of Klingnau - not far from PSI.
Chemistry
14.06.2017
Universal stabilisation
Universal stabilisation
ETH researchers led by Lucio Isa have developed microparticles with a rough, raspberry-like surface that stabilise emulsions following a new principle.
Medicine/Pharmacology - Life Sciences
13.06.2017
Boost for Zurich biomedicine
Boost for Zurich biomedicine
The Helmut Horten Foundation has supported Zurich's medical hub for many years. Now, a new donation to ETH will enable the strengthening of the Zurich-Ticino ‘health axis'.
Medicine/Pharmacology - Physics/Materials Science
13.06.2017
New "WHO Collaborating Centre for Physical Activity and Health"
A lack of physical activity increases the risk for cardiovascular and respiratory diseases as well as diabetes and cancer.
Life Sciences - Medicine/Pharmacology
12.06.2017
Fighting fire blight and detecting Salmonella
Fighting fire blight and detecting Salmonella
ETH researchers have created an effective weapon against the plant disease fire blight and a new method for detection of Salmonella. Both are based on particular viruses that attack only one species of bacteria. The plant disease fire blight, caused by the bacterium Erwinia amylovora , is dreaded by fruit growers.
Computer Science/Telecom
12.06.2017
Smarter use of mobile data
Smarter use of mobile data
The data constantly collected and reported by smartphones can find numerous applications. An SNSF-funded project devoted to crowdsensing has found ways to improve privacy and localisation accuracy as well as reduce the impact on hardware. Connecting data from the world's smartphones could put a global supercomputer into all of our pockets.
Life Sciences - Medicine/Pharmacology
12.06.2017
Uncovering the biology of a painful and disfiguring pediatric disease
Uncovering the biology of a painful and disfiguring pediatric disease
EPFL scientists have identified the biological mechanism behind the painful, potentially lethal, disfiguring Hyaline Fibromatosis Syndrome.‚? Image caption:‚?Loss of ANTXR2 leads to the accumulation of extracellular material in mice uterus and sterility (Left). Collagen 6 removal in mice without ANTXR2 restore uterine structure and function (Right).
Life Sciences - Mathematics
12.06.2017
Hidden patterns of brain activity
In a collaboration led by EPFL‚?‘s Blue Brain, scientists discover patterns of brain activity ‚'' never before observed ‚?- with the help of mathematics, providing insight into how neurons collectively process information. Brains of healthy rats that are the same age share many features, such as similar numbers and types of neurons present in the six layers of the cortex.
Medicine/Pharmacology - Business/Economics
09.06.2017
Hybrid membrane creates a stir on the global market
Hybrid membrane creates a stir on the global market
ETH Professor Raffaele Mezzenga and his senior researcher Sreenath Bolisetty have developed a filter membrane that efficiently removes heavy metals and other toxic substances from water. Strong demand for the new technology has encouraged them to set up a new ETH spin-off, BluAct Technologies. The news story made a big splash: in January 2016 ETH researchers Professor Raffaele Mezzenga and his senior researcher Sreenath Bolisetty published a study about an innovative type of membrane developed in their laboratory.
Chemistry - Physics/Materials Science
09.06.2017
Graphene electrodes offer new functionalities in molecular electronic nanodevices
Graphene electrodes offer new functionalities in molecular electronic nanodevices
Media releases, information for representatives of the media Media Relations (E) An international team of researchers led by the University of Bern and the National Physical Laboratory (NPL) has revealed a new way to tune the functionality of next-generation molecular electronic devices using graphene.
Life Sciences - History/Archeology
09.06.2017
Ancient Bones Reveal Insights Into Swiss Wild Horse Population
Researchers from the University of Basel have, for the first time, studied how regional environmental changes influenced the populations of wild horses in Switzerland 25,000 years ago. Their results show: Contrary to the wild horses in the Eurasian steppe; the Swiss population grew considerably after the end of the last Ice Age.
Administration/Government
08.06.2017
Mobilizing Swiss Research in Asia
Mobilizing Swiss Research in Asia
ETH Zurich to serve as the Leading House for Swiss Science and Technology programme in the Asia-Pacific region.
Medicine/Pharmacology - Life Sciences
08.06.2017
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month ‚?
Medicine/Pharmacology - Life Sciences
07.06.2017
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achi
Mathematics - Medicine/Pharmacology
07.06.2017
Your own virtual heart for non-invasive heart diagnostics
EPFL mathematician Alfio Quarteroni and his team are building a virtual heart model based on personalized medical images that may one day help cardiologists and cardiac surgeons non-invasively diagnose pathological heart conditions.
Life Sciences - Physics/Materials Science
07.06.2017
More concepts, fewer facts
More concepts, fewer facts
ETH biology lecturers have tested secondary school leavers and students to determine their knowledge of biological concepts.
Medicine/Pharmacology - Chemistry
06.06.2017
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna in Ph+ CML-CP patients in both the first-line setting and after switching from Glivec ‚?
Life Sciences
06.06.2017
New findings could lead to improved in vitro testing
New findings could lead to improved in vitro testing
EPFL researchers propose a new approach of performing in vitro tests on nanoparticles that could enhance a correlation to in vivo results. This involves reproducing in the lab the dynamic and fluidic variations that these particles experience in the human body. Before new nanoparticles or other nanomedicines can be injected into the human body, a whole series of tests must be conducted in the laboratory, then in living cells, and in the end on humans.
Medicine/Pharmacology - Life Sciences
05.06.2017
Phase III study showed Roche‚? s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Phase III study showed Roche‚??s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system Data will be simultaneously pub
Medicine/Pharmacology - Computer Science/Telecom
05.06.2017
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
Collaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer Brings Novartis innovation and breast cancer expertise together with IBM Watson Health proficiency in data analytics and machine learning Collaboration initiating in breast cancer given Novartis heritage and expertise; opportunity to expand to enhance outcomes for patients with other cancers ‚‘‚'‚‘‚'‚‘‚'‚‘‚'‚‘‚'‚‘‚' ‚?
Medicine/Pharmacology - Administration/Government
05.06.2017
Roche‚? s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
APHINITY study shows Roche‚??s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Phase III study confirms
Medicine/Pharmacology
05.06.2017
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
Phase I/II study to evaluate Mekinist ‚? (trametinib) in combination with Opdivo ‚? (nivolumab) and Opdivo + Yervoy ‚? (ipilimumab) ‚? Collaboration expands upon existing clinical investigation of Op
Medicine/Pharmacology - Life Sciences
04.06.2017
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma Study is longest follow-up to date o
Medicine/Pharmacology - Life Sciences
03.06.2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Data evaluated TECENTRIQ in novel combinations across a broad range of tumours including lung, kidney and melanoma Promising Phase II combination data with TECENTRIQ plus Avastin (bevacizumab) in advanced kidney cancer First treatment-beyond-progression data from a Phase III study of cancer immunotherapy in a
Media - Administration/Government
02.06.2017
Medicine/Pharmacology - Life Sciences
02.06.2017
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer At a subsequent
Business/Economics - Environment/Sustainable Development
02.06.2017
Emissions trading scheme: acquisition of aviation data in 2018
Bern, 02.06.2017 - The integration of greenhouse gas emissions from the aviation sector into the emissions trading scheme (ETS) is a necessary step in order to link the Swiss and European schemes.
Medicine/Pharmacology - Life Sciences
02.06.2017
A new approach to combatting anxiety states, pain and inflammation
A new approach to combatting anxiety states, pain and inflammation
Media releases, information for representatives of the media Media Relations (E) Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research (NCCR) "TransCure" have now found a new way to influence the endocannabinoid system.
Environment/Sustainable Development
01.06.2017
Research on road construction
Research on road construction
This year, Empa plays host to the biennial conference of the European Asphalt Technology Association (EATA).
Life Sciences
01.06.2017
New research tools
New research tools
At the age of 29, biotechnologist Randall Platt has already achieved a lot: more than 1,000 research laboratories around the world use a method that he developed.
Environment/Sustainable Development - Earth Sciences
01.06.2017
Landscapes remain under pressure
Bern, 01.06.2017 - Landscapes play an important role in Switzerland's quality of life and attractiveness as a location. They remain under considerable pressure: the latest results of the Landscape Monitoring Switzerland programme reveal a continuous deterioration in the quality of the country's landscapes.
Medicine/Pharmacology
31.05.2017
Progress reported in global fight against diarrheal disease cryptosporidiosis
Novartis, the University of Georgia, Washington State University and collaborators advance therapeutic research for cryptosporidiosis Research collaboration with novel drug discovery process counters slow progress in developing new cryptosporidiosis treatments Scientists report discovery of Cryptosporidium PI(4)K inhibitor candidate KDU731 in new issue of Nature - Infectious disease scientists from Novartis, the University of Georgia and Washing
Civil Engineering/Traffic Engineering - History/Archeology
31.05.2017
The man with cities on his mind
The man with cities on his mind
Vittorio Magnago Lampugnani hasn't just written definitive reference works on urban planning and shaped a generation of ETH architects; he has also run numerous projects of his own.
Medicine/Pharmacology - Business/Economics
31.05.2017
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018 Building depth across key therapeutic areas wi
Medicine/Pharmacology - Life Sciences
31.05.2017
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira * and Remicade ** Comprehensive data pac
Medicine/Pharmacology - Life Sciences
31.05.2017
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months. CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of Pennsylvania Novartis is committed to advancing a portfolio of next-generation CAR-T cell therapies - Novartis announced findings from a pilot study (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in complete remission.
Medicine/Pharmacology - Life Sciences
30.05.2017
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Drug resistance is not only a major problem in fighting infectious diseases. Also in the treatment of cancer it can jeopardize the success of chemotherapy.
Physics/Materials Science - Microtechnics/Electroengineering
30.05.2017
New Method of Characterizing Graphene
New Method of Characterizing Graphene
Scientists have developed a new method of characterizing graphene‚?‘s properties without applying disruptive electrical contacts, allowing them to investigate both the resistance and quantum capacitance of graphene and other two-dimensional materials. Researchers from the Swiss Nanoscience Institute and the University of Basel‚''s Department of Physics reported their findings in the journal Physical Review Applied.
Physics/Materials Science - Business/Economics
29.05.2017
To the limits of the feasible
First, the engineers and the physicists had to find each other. Then, however, the company Daetwyler built the undulators for the free-electron X-ray laser SwissFEL of the Paul Scherrer Institute PSI as precisely as was possible: to one-tenth of the width of a hair.
Careers/Employment - Environment/Sustainable Development
26.05.2017
Managing an eco-friendly house with Lego-like technology bricks
Managing an eco-friendly house with Lego-like technology bricks
Thanks to startup ThinkEE's modular system - which consists of technology bricks linking various connected devices - data from a host of sensors can be collected regardless of the sensors' protocols.
Environment/Sustainable Development - Business/Economics
26.05.2017
Natural disasters and climate-related risks: Switzerland appeals for closer links between disaster risk reduction, climate change and development cooperation
Natural disasters and climate-related risks: Switzerland appeals for closer links between disaster risk reduction, climate change and development cooperation Bern, 26.05.2017 - Natural disasters and climate-related risks threaten to reverse hard-won gains in development.
Medicine/Pharmacology - Life Sciences
26.05.2017
Designer Viruses Stimulate the Immune System to Fight Cancer
Swiss scientists have created artificial viruses that can be used to target cancer. These designer viruses alert the immune system and cause it to send killer cells to help fight the tumor. The results, published Communications, provide a basis for innovative cancer treatments. Most cancer cells only provoke a limited reaction from the immune system - the body's defense mechanism - and can thus grow without appreciable resistance.
Medicine/Pharmacology - Life Sciences
26.05.2017
Novartis receives FDA approval for expanded use of Zykadia in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy † The overall intracranial response r
Medicine/Pharmacology - Administration/Government
24.05.2017
New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)
New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet reduced the risk of death in p
Physics/Materials Science - Chemistry
23.05.2017
Soot particles from GDI engines
Soot particles from GDI engines
Are new gasoline cars environmentally friendly? Not always, says a new study led by Empa scientists: some direct-injection gasoline engines emit just as many soot particles as unfiltered diesel cars did in the past.
Life Sciences - Medicine/Pharmacology
23.05.2017
Revealing how neurons communicate
Revealing how neurons communicate
The ETH spinoff MaxWell Biosystems AG develops microelectrode platforms for electrophysiological tests on nerve cells, opening up new possibilities for pharmaceutical research. Now, the company received CHF 130,000 in starting capital from the Venture Kick initiative MaxWell Biosystems AG's head office is hidden away in a Basel laboratory building previously used by Syngenta, just a stone's throw from ETH Zurich's Department of Biosystems Science and Engineering (D-BSSE).
Physics/Materials Science - Microtechnics/Electroengineering
23.05.2017
High voltage for tomorrow's particle accelerator
High voltage for tomorrow’s particle accelerator
On behalf of CERN, researchers at ETH Zurich have developed a high-tech device for the production of extremely precise, high voltage pulses that could be used in the next generation of particle accelerators.
Careers/Employment
23.05.2017
Swiss Labour Force Survey in 1st quarter 2017: labour supply: 1st quarter 2017: 0.6% increase in the number of employed persons. The unemployment rate based on the ILO definition settles at 5.3%
1st quarter 2017: 0.6% increase in the number of employed persons. The unemployment rate based on the ILO definition settles at 5.3% Neuch‚tel, 19.05.2017 (FSO) - The number of employed persons in Switzerland rose by 0.6% between the 1st quarters of 2016 and 2017.

 
 
Logo Careerjet